Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.

Next Previous
X
Search
Trial Profile

Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Yttrium-90 (Primary)
  • Indications Cholangiocarcinoma; Liver metastases
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 Sep 2019 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top